This post is from a suggested group
Minimal Residual Disease Testing: Advancing Cancer Care
Minimal Residual Disease (MRD) testing has emerged as a transformative approach in modern oncology, allowing clinicians to detect microscopic traces of cancer that remain after treatment. Unlike conventional imaging or laboratory tests, MRD testing is highly sensitive and can identify residual cancer cells even when a patient appears to be in complete remission. This precision offers a significant advantage in predicting relapse, guiding therapy decisions, and improving long-term patient outcomes.
MRD testing is most commonly applied in hematologic cancers such as leukemia, lymphoma, and multiple myeloma. In these conditions, even a small number of leftover cancer cells can lead to relapse if not addressed. By detecting MRD, doctors can determine whether additional treatment is necessary or if a patient can safely avoid more intensive therapies. This personalized approach not only increases survival chances but also minimizes unnecessary exposure to potentially harmful medications.
Technological…